GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Accounts Receivable

Mabpharm (HKSE:02181) Accounts Receivable : HK$21.24 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Mabpharm's accounts receivables for the quarter that ended in Dec. 2023 was HK$21.24 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Mabpharm's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 82.16.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Mabpharm's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$-0.16.


Mabpharm Accounts Receivable Historical Data

The historical data trend for Mabpharm's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Accounts Receivable Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial - - 0.97 10.65 21.24

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 4.51 10.65 31.73 21.24

Mabpharm Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Mabpharm Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Mabpharm's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=21.244/47.187*91
=82.16

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Mabpharm's accounts receivable are only considered to be worth 75% of book value:

Mabpharm's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(189.601+0.75 * 21.244+0.5 * 111.606-907.745
-0-0)/4124.08
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Mabpharm Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Mabpharm's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabpharm (HKSE:02181) Business Description

Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines